Novartis names Indianorigin Vasant Narasimhan as new CEO
have lost patent protection, while eye business Alcon has lagged expectations and generics arm Sandoz has faced pressure on prices in the US.
Novartis got a boost last week, when the US approved its $475,000-per-patient Kymriah treatment for young people with B-cell acute lymphoblastic leukemia, one of the new drugs it expects to revive sales growth from next year.
Jimenez, 57, said on Monday now was a good time to move on. “I really believe a leader has to be in place at the beginning of that growth phase to see it through. And that wouldn’t be me, given that I’m eight years into my tenure.”
Narasimhan, 41, is among a new generation of youthful leaders at Novartis, including head researcher Jay Bradner at the Novartis Institutes For Biomedical Research.
Together, they have sought to improve the company’s way of moving drugs from the laboratory into commercial products, something they acknowledge has not always worked efficiently.
“That’s going to continue to be the focus of the company: To translate that innovation into commercial success,” said Narasimhan, a US citizen.
Analysts said Narasimhan’s skills as a Harvardtrained medical doctor and former McKinsey consultant may be the blend Novartis needs to balance research and business. “The appointment ... brings deep medical and commercial knowledge plus strong communication, and we expect this fresh start to be taken very well by the markets,” said David Evans, a Kepler Cheuvreux analyst.
But there will be plenty in Narasimhan’s in-tray.
His appointment comes as Novartis is reviewing Alcon for a possible sale that could bring in $25-$35 billion.
He must also decide what to do with its $10 billion stake in its over-the-counter drugs venture with GlaxoSmithKline. Novartis faces a deadline of March 2018 to decide whether to exercise a sell option for its 36.5% stake.
Narasimhan will have to weigh up too what to so with Novartis’s $14-billion stake in rival Roche, which the company has said could be sold.
Novartis shares have lagged the Stoxx European Health Care Index by around 9% during Jimenez’s tenure.
Having held various roles at Novartis since 2005, Narasimhan became global head of drug development and chief medical officer in 2016.